Introduction
Sub-Saharan Africa, especially East and Southern Africa, has the highest burden of HIV infection in the world [1] .
Substantial progress has been made in reducing the gap between those who need and those who receive antiretroviral therapy (ART), and in the coverage of interventions to prevent mother-to-child transmission (PMTCT) of HIV. In Southern Africa, ART coverage among adults increased by 10-32% in 2007 and PMTCT coverage was 43% [2] . For HIV-infected children, however, the treatment gap remains disproportionately high throughout the developing world [2] .
HIV is less well characterized in children and adolescents (defined by the World Health Organization as children aged between 10 and 19 years) than in adults and the number of, and prognosis for, those with untreated paediatric HIV remains uncertain. In the absence of drug treatment, about one-third of infants born to HIVinfected mothers will be infected during pregnancy, birth, or breastfeeding [vertical or mother-to-child transmission (MTCT)] [3] . Until recently, it was assumed that few HIV-positive vertically infected children survived beyond the age of 5 years [4] . However, a pooled cohort analysis estimated that at least 13% of such children will survive to age 10 years [5] and more recent projections suggest that 17% will survive to age 15 years [6] .
Most population-based HIV prevalence surveys excluded children between the age of 5 and 15 years, although they have been included in recent surveys in Zimbabwe [7] , South Africa [8, 9] , Botswana [10, 11] , and Swaziland [12] , and in all of these countries a substantial burden of HIV has been reported in this age group. In Zimbabwe, in particular, increasing numbers of HIV-positive adolescents are presenting with severe stunting, pubertal delay, and a history of chronic ill health, consistent with long-standing infection but with little to suggest risk of transmission through routes other than MTCT [13] . Studies from other countries in the region confirm that considerable numbers of HIV-infected older children are presenting for care [14] . There has, however, been little planning or provision of HIV testing or treatment services for this age group.
We use data on time trends in the prevalence of HIV among women attending antenatal clinics and on survival in children to estimate the prevalence of infection in older survivors of MTCT and compare our estimates with data on the prevalence of HIV in children in population surveys, on the age distribution of children receiving ART in South Africa and the age distribution of HIVinfected children in clinical care in Zimbabwe.
Methods and data sources
Demographic data Population data were taken from the Population Division of the United Nations (UNPOP) database [15] . The data, given in 5-year age bands, were interpolated to 1-year age bands up to 1980 using cubic-splines. We used crude birth and death rates from the UNPOP database up to the start of the HIV epidemic [15] and use our model to project birth and death rates forward in time.
Trends in the adult prevalence of HIV Data from antenatal HIV prevalence surveys in South Africa [16] , Botswana [17] , Swaziland [18] and from National HIV and AIDS Estimates for Zimbabwe [19] were used to estimate the number of HIV-positive pregnant women in each country. In order to estimate the HIV prevalence and mortality in adults, which we do only to estimate the relative size of the epidemic in adults and in children, we scale the data to fit UNAIDS national estimates of HIV in adults [1] .
Survival of vertically infected children
The model predictions depend mainly on the prevalence of HIV in pregnant women and the survival distribution of vertically infected children. Since cohort studies of children infected by their mothers have not been continued for more than 5 years we combine these data [5, 6] with data from the CASCADE cohort, a metaanalysis of 38 studies in developed countries which determined survival as a function of age and included children infected before the age of 5 years ( Fig. 1 ) [20] . We fitted the data to an exponential survivor function for the fast progressors and a Weibull survival function for the slow progressors so that the survival, S(t), is given by:
SðtÞ ¼ a eÀbt þ ð1 À aÞ 2Àðt=mÞ s (1) where the proportion of fast progressors is a, and of slow progressors is 1Àa. The least-squares parameter estimates are a ¼ 0. Data from Rakai, red triangle (no error bars); Kampala, blue dots; Abidjan, brown dots; Nairobi, black square; Durban, purple square; and Kigali, orange square [8] ; Harare, dark blue diamond [25] ; Africa, light green dots [4] ; developed countries, black dots [26] . The fitted (red line) line is the sum of an exponential for the fast progressors and a Weibull (pink line) for the slow progressors as described in the text.
Modelling adult incidence, prevalence and mortality
We fitted a compartmental model to time trends in the prevalence of HIV among adults ( Fig. 2 ) and used the model to estimate time trends in adult incidence and mortality in order to be able to compare the predictions for children with those for adults. Details of the model of adult transmission have been published elsewhere [21] .
Age-specific prevalence and mortality rates for infants and older children
The birth rate combined with HIV prevalence among adult women was used to estimate the number of children born to HIV-positive mothers over time for different options for PMTCT interventions. This, with the survival distribution (Eq. 1), determines the prevalence and mortality, of fast and slow progressors.
PMTCT interventions
We assume that the probability of MTCTwill be reduced from 35% (mixed breastfeeding) to 16% with single-dose nevirapine and exclusive breastfeeding, and to 2% with highly active antiretroviral therapy (HAART) and exclusive breastfeeding [6] . We estimate the impact of increasing the coverage of these two PMTCT interventions starting in 2000, reaching 40% by 2005 and levelling off at 80% in 2010, and assuming that the interventions affect fast and slow progressors equally.
Other data sources
To investigate the validity of the model we use agespecific data on individuals in HIV care nationally in Zimbabwe [22] , and from a cohort of individuals registered at HIV care clinics in South Africa run by the Catholic Bishops Conference, which provides ART to resource-poor communities in South Africa [23] . We also compare the predicted prevalence of HIV to data from national prevalence surveys in three countries: Botswana [10] , South Africa [9] , and Swaziland [12] . We assume that the specificity was 99.5% for blood-based HIV tests and 98% for oral mucosal transudate-based tests [24] .
Results
We estimated the age-specific incidence, prevalence and mortality for vertically infected slow progressors and for adults and examined the potential impact of PMTCT on these outcomes.
Prevalence of HIV in South Africa and Zimbabwe among slow progressors without PMTCT
We predict substantial epidemics of HIV in adolescent survivors in both countries. In South Africa, the prevalence of vertically acquired HIV among 10-yearolds has probably increased from less than 0.2% in 2000 to 2.1% in 2008, and is expected to reach 3.3% by 2020 if no PMTCT is provided. In Zimbabwe, where adult HIV prevalence peaked in the late 1990s and has since declined [19] , the corresponding prevalence reached a peak of 3.2% in 2008, and is projected to fall to 1.6% in 2020 ( Fig. 3a) .
The age-specific prevalence of HIV-positive slow progressors at 5-year intervals from 1995 to 2020 is shown in Fig. 3b and c. In South Africa, where the adult HIV epidemic is about 10 years behind that in Zimbabwe, the prevalence of slow progressors increases until 2020 ( Fig. 3b ). In 1995 the adult epidemic of HIV in South Africa was still relatively new and the few infected slow progressors had to have been infected in the previous 5 years. By 2020, assuming that the epidemic stabilizes ( Fig. 2) , the age-specific prevalence reflects the Weibull survival curve (Eq. 1). In Zimbabwe, the prevalence of slow progressors increases up to 2013 and declines thereafter, but the mean age of the slow progressors increases steadily as the adult epidemic falls giving rise to fewer new infections among slow progressors ( Fig. 3c ).
AIDS deaths attributable in South Africa and Zimbabwe without PMTCT
As shown in Fig. 4a and b, the high median survival in slow progressors implies a substantial time lag between the epidemics of AIDS deaths in adults and slow progressors. In South Africa, without treatment, deaths in vertically infected slow progressors will increase from 7000 per year in 2008 to 23 000 per year in 2030 ( Fig. 4a ) when the mean age of those dying will be 15 years (Fig. 4c ). In Zimbabwe these deaths will increase from 8000 per year in 2008 to a peak at 9700 per year in 2014 ( Fig. 4b) , when the mean age of those dying will be 16 years (Fig. 4d ), and will decline to 7500 per year in 2030 when the mean age will be 18 years.
In South Africa, infant AIDS deaths among rapid progressors will continue to outnumber those in slow progressors (Fig. 4a ), whereas in Zimbabwe adolescent slow progressors will outnumber infant fast progressors after 2012 (Fig. 4b ).
In our model, deaths among slow progressors do occur in infancy although infrequently. In the early years of the adult HIV epidemic all slow progressors will still be young, so deaths among slow progressors can only be at a young age. AIDS deaths among slow progressors may still be less apparent clinically than AIDS deaths among fast progressors in 2011, despite being almost equal in number, because slow progressors span a much wider age range.
The potential impact of PMTCT interventions on AIDS deaths in South Africa and Zimbabwe HIV prevalence and deaths among fast progressors begin to fall very soon after PMTCT interventions are implemented ( Fig. 4a and b ), but much more slowly among adolescents, reflecting their longer survival. The most potent intervention (ART for mothers and babies and breast feeding) will halve HIV-related mortality by 2010 in 5-year-olds, and by 2020 in 15-year-olds in both Zimbabwe and South Africa. The number of deaths among slow progressors in 2030 could be reduced from 23 000 to 8700 per year in South Africa and from 7500 to 2800 per year in Zimbabwe. Nevirapine with exclusive breast feeding will only reduce mortality by about 57% as much.
Potential role of clinical and national survey data for providing estimates of median survival of slow progressors Figure 3b shows the age distribution of children in the South African Catholic Bishops Cohort [25] superimposed on our estimates of HIV prevalence, and Fig. 3c shows the age distribution of children in HIV care in Zimbabwe. The age distribution of children in both countries is close to the estimated age-specific prevalence predicted by our model.
In Fig. 5 we use our model to predict the prevalence of HIV in children and adolescents in Botswana, Swaziland and South Africa. It is important to note that the model is not fitted to the data, so that the comparison is direct, and the only adjustment to the data is for the assumed specificity of the HIV tests. The agreement between model estimates and observed data give support for the model and underlying assumptions and suggests ways in which the validity of the model can be explored further. Finally, we can now use these data to examine the sensitivity of the results to changes in the survival distribution of slow progressors by varying their median survival and determining the lower limit that is consistent with the data in Fig. 5 . The lower 95% confidence limits are then 12.2 years for Botswana, 7.4 years for South Africa and 12.4 years for Swaziland giving strong support to the assumption in Fig. 1 that the long-term survival follows the distribution found for those infected before the age of 4 years in developed countries.
Discussion
The starting point for this study was the increasing evidence of frequent, prolonged survival among untreated vertically infected HIV-positive children [8, 13, 14] . Available data suggest that about one-third of infected African infants are slow progressors with a median life expectancy of about 16 years [5, 6] , and this analysis provides strong support for a substantial and prolonged epidemic of HIV-infected older children, with a considerable number of survivors reaching late adolescence.
The epidemic of slow progressors emerges slowly and leads to a persistent epidemic of HIV-infected survivors, with numbers of older survivors continuing to increase for 10-20 years after the HIV epidemic in adults has peaked and peak mortality occurring even later. These dynamics contrast sharply with the much more immediately obvious epidemic of infant deaths among fast progressors, and may help to explain why the scale of the epidemic in long-term survivors of MTCT has only recently been recognized.
An additional factor is that children infected postnatally through breast feeding may be more likely to be slow progressors than those infected in utero or intrapartum [26, 27] . The immune system undergoes major changes in the postpartum period, shifting away from active acquisition of self-tolerance in utero towards defensive responses to antigens encountered postnatally [28] , and the timing of HIV infection could have a critical impact on the anti-HIV immune response. Infants infected after the first few weeks of life have significantly lower peak viral loads and lower viral set-points than those infected earlier, and have substantially lower mortality rates [26, 29, 30] .
If timing of infection affects the likelihood of slow progression, then the emerging African epidemic may have a natural history that is different from those in developed countries because of differences in infant feeding practices.
In developed countries formula feeding is almost universal among HIV-infected mothers [31] , whereas in Africa most mothers breastfeed their babies even if they know that they are infected with HIV [8] . Breastfeeding approximately doubles the risk of vertical HIV transmission, with a third of transmission events from breast milk occurring after 6 months [32] . Thus, in addition to the much higher HIV prevalence among infants in Africa, a higher proportion of these may be slow progressors.
Both South Africa and Zimbabwe are now scaling up PMTCT programs, with the aim of achieving universal coverage by 2010. However, coverage of PMTCT was only 57% in South Africa and 29% in Zimbabwe in 2007 [2] , and PMTCT will not affect the current cohort of surviving children who have slowly progressing HIV infection that was acquired before the recent scale-up of services. Potentially, the scale-up of PMTCT programmes may further increase the proportion of vertical HIV infections that are acquired after the first few weeks of life, although reducing the overall burden of infected infants.
In spite of the increasingly apparent epidemic of slow progressors in Southern Africa, surviving older children and adolescents are still very poorly served by routine HIV testing and care services [33] . As well as systematic under-appreciation of the burden of HIV in this age group, the need for parental or guardian consent presents considerable barriers to HIV testing in minors. Older survivors of vertical HIV infection are mostly orphaned and often impoverished by parental ill health [34] . Routine diagnosis is usually made only after several years of increasingly poor health, by which time children have lost years of schooling and are at high risk of avoidable but irreversible chronic complications of HIV [13] . Added to this is an expanding cohort of children with more rapidly progressing HIV who would have died but are now likely to survive to adolescence because of ART [35] . Furthermore, as increasing numbers of children enter adolescence and become sexually active, it is likely that onward horizontal HIV transmission will contribute to ongoing adult HIV epidemics.
The study is limited by the lack of reliable age-specific cohort data on which to base projections, highlighting the need for much better monitoring and for more comprehensive data pertaining to HIV among older children. The estimated median survival of 16 years for slow progressors was based on data from the CASCADE cohort [20] . However, these children were infected mainly from contaminated blood products and, because they were all from developed countries, their survival may be different from the survival of vertically infected slow progressors in Africa. The national HIV prevalence surveys often have low participation rates and the specificity of the HIV tests used in the surveys is uncertain. The data reported by the Catholic Bishops in South Africa, used for comparison with model projections, may over-represent older children and adolescents due to the programme's special focus on orphans, and provision of HIV care would improve survival.
The median survival of slow progressors plays a critical role in determining the magnitude and duration of the HIV epidemic in older survivors of MTCT but cohort studies to estimate this parameter would require a very long follow-up that would not now be feasible given the increasing availability of ART. However, it may be possible to obtain indirect evidence of the distribution of survival through much more extensive prevalence surveys than have so far been carried out, through data from health facilities implementing provider-initiated or routine HIV testing and from data on the age distribution of patients entering clinical care with HIV.
Service provision has been adversely affected by the underappreciation of the numbers of surviving older children and adolescents living with HIV in Africa. The need to consider HIVas a cause of ill health in older children has not been emphasized to health providers, and little or no provision has been made for the special needs of this age group. While awaiting more precise projections there is an urgent need to develop and rapidly implement policies and programmes aimed at providing early diagnosis, treatment and care including secondary prevention services to the expanding numbers of children and adolescents who are growing up with HIV.
